Cytokines in PD-1 immune checkpoint inhibitor adverse events and implications for the treatment of uveitis.

Autor: Brown AC; Department of Ophthalmology, New York Eye and Ear Infirmary of Mount Sinai, 310 E 14th Street, New York, NY, 10003, USA.; Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Quiroz J; Department of Ophthalmology, New York Eye and Ear Infirmary of Mount Sinai, 310 E 14th Street, New York, NY, 10003, USA.; Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Parikh DA; Department of Ophthalmology, New York Eye and Ear Infirmary of Mount Sinai, 310 E 14th Street, New York, NY, 10003, USA.; Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Li Y; Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA., Ritzer L; Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Rosen R; Department of Ophthalmology, New York Eye and Ear Infirmary of Mount Sinai, 310 E 14th Street, New York, NY, 10003, USA.; Einhorn Clinical Research Center, New York Eye and Ear Infirmary of Mount Sinai, New York, NY, USA., Deobhakta A; Department of Ophthalmology, New York Eye and Ear Infirmary of Mount Sinai, 310 E 14th Street, New York, NY, 10003, USA. adeobhakta@NYEE.EDU.; Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. adeobhakta@NYEE.EDU.
Jazyk: angličtina
Zdroj: BMC ophthalmology [BMC Ophthalmol] 2024 Jul 29; Vol. 24 (1), pp. 312. Date of Electronic Publication: 2024 Jul 29.
DOI: 10.1186/s12886-024-03575-7
Abstrakt: Immune checkpoint inhibitors (ICI) such as Programmed cell Death 1 (PD-1) inhibitors have improved cancer treatment by enhancing the immune system's ability to target malignant cells. Their use is associated with immune-related adverse events (irAEs), including uveitis. The profile of pro-inflammatory cytokines underlying Anti-PD-1-induced uveitis shares significant overlap with that of non-infectious uveitis. Current corticosteroid treatments for uveitis while effective are fraught with vision threatening side effects. The cytokine profile in ICI-related uveitis has a large overlap with that of noninfectious uveitis, this overlap strongly supports the potential for therapy that activates the PD-1 axis in the eye to treat uveitis. Indeed, ICI related uveitis often resolves with cessation of the ICI, restoring the endogenous PD-1 axis. The potential benefit of targeting many pro-inflammatory cytokines via local PD-1 axis activation is mitigating ocular inflammation while minimizing adverse effects.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: